Cantor Fitzgerald Predicts Metsera FY2026 Earnings

Metsera, Inc. (NASDAQ:MTSR) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Metsera in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($3.81) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

A number of other analysts have also recently weighed in on the company. Evercore ISI assumed coverage on Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Bank of America assumed coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Finally, Guggenheim raised their price target on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday.

Metsera Trading Down 5.8%

MTSR opened at $33.06 on Wednesday. Metsera has a one year low of $12.30 and a one year high of $37.99. The firm has a 50-day simple moving average of $23.72.

Metsera (NASDAQ:MTSR) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MTSR. Strs Ohio acquired a new position in shares of Metsera during the first quarter worth about $76,000. New York State Common Retirement Fund bought a new stake in Metsera in the first quarter valued at about $131,000. Corebridge Financial Inc. bought a new stake in Metsera in the first quarter valued at about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Metsera during the first quarter valued at approximately $248,000. Finally, MetLife Investment Management LLC bought a new position in shares of Metsera during the first quarter valued at approximately $254,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.